Live Breaking News & Updates on Sophie Gray Gaillard

Share this article
Share this article
NEW YORK, March 9, 2021 /PRNewswire/ Patients previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may produce levels of antibodies against COVID-19 after a one dose of the Pfizer Inc./BioNTech SE messenger RNA (mRNA) vaccine that are equal to or higher than people not previously infected have after two doses, a new study finds.
Presented virtually March 9 at the Conference for Retroviruses and Opportunistic Infections (CROI), the results of the small, exploratory study also suggest that the immune responses in most patients previously infected with the pandemic virus did not improve further after a second vaccination. ....

Jimmy Wilson , Joseph Allen , Marie Samanovic , Trishala Karmacharya , Gregory Williams , Amber Cornelius , Markj Mulligan , Ramin Herati , Sara Hyman , Sophie Gray Gaillard , Centers For Disease , Public Health Importance , Langone Health , National Institutes Of Health , Division Of Infectious Diseases , Drug Administration On , Grossman School Of Medicine , Study Team , Vaccine Center , Pfizer Inc Biontech , Pfizer Inc , Opportunistic Infections , Emergency Use Authorization , Drug Administration , Infectious Diseases , Disease Control ,